Pixium Vision Expands Collaboration with Stanford University On Next Generation Prima System Implants
Pixium Vision SA announced the expansion of a collaboration with academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration (AMD).
“We are very excited to be extending our collaboration with Stanford University, with whom we have built an excellent working relationship over a number of years,” Guillaume Buc, Chief Technology Officer of Pixium Vision, said in a company news release. “Our agreement with Stanford University provides Pixium Vision access to leading research in the field, and we believe the development of this new implant will help further improve the vision of patients suffering from dry-AMD. Our internal R&D team continues to enjoy a synergistic working relationship with Stanford and we look forward to leveraging this even further in our future pipeline development initiatives.”
“We are extremely fortunate to be working together again with Pixium Vision,” said Professor Daniel Palanker from the Department of Ophthalmology at Stanford University. “I am very proud of what we achieved with the first generation of PRIMA implants that are currently continuing to advance through clinical development with the PRIMAvera pivotal study with an anticipated data readout in early 2023, and I am looking forward to seeing how much further we can advance with the second generation.”
The new generation of implants will use a similar PRIMA design and components while potentially allowing for a significantly greater amount of targeted neural stimulation. This will be achieved through an exponential increase in the number of pixels in the new implant.
The original agreement between Pixium Vision and Stanford University was signed in 2014 and laid the foundation for the creation of the PRIMA design. Financial terms of this new agreement have not been disclosed but are similar to the financial agreements signed in 2014.